Drug Manufacturing: Sonication Is Shaping the Future of Biogenic Medicines

Ultrasound is no longer just a laboratory tool. In pharmaceutical manufacturing, sonication is emerging as a powerful enabling technology for the production of biogenic drugs – medicines derived from natural biological sources that combine efficacy with sustainability. Here we present the results of a new research on broccoli-mediated gold nanoparticles, which illustrates how ultrasonic processing bridges green chemistry and advanced drug design.

So what happens when high-intensity ultrasound meets plant biochemistry?

From Broccoli to Biogenic Drugs

Biogenic drug manufacturing relies on bioactive molecules such as polyphenols, flavonoids, glucosinolates, and peptides. These compounds can act as reducing agents, stabilizers, and even therapeutic moieties. However, extracting and activating them efficiently has always been a bottleneck.

In a recently published study, researchers demonstrated that aqueous broccoli extract can be used to synthesize gold nanoparticles with pronounced antioxidant, wound-healing, and selective anticancer properties. Crucially, the synthesis was performed under ultrasonic irradiation using the 200 watts sonicator model UP200St (Hielscher Ultrasonics, picture left). Sonication was not a passive step – it was the driving force that enabled rapid nanoparticle formation, controlled size distribution, and stable biofunctional surfaces.

Within minutes, ultrasound-induced cavitation created localized high-energy micro-environments. These conditions accelerated the reduction of gold ions while preserving the delicate phytochemicals responsible for biological activity.
The result? Uniform, ultra-small gold nanoparticles capped with broccoli-derived biomolecules and tailored for biomedical use.

This is precisely where industrial sonication shows its strength.

Green synthesis of AuNPs using Brassica oleracea extract. The aqueous extract serves as both a reducing and a stabilizing agent during the ultrasonic synthesis process. Chloroauric acid is added dropwise to the broccoli extract under sonication with the UP200St sonicator, followed by incubation at 4◦C for 24 h to allow nanoparticle formation. The colloidal suspension is then subjected to a secondary sonication and centrifugation to remove unreacted components, yielding purified AuNPs with stable dispersion.

Why Sonication Matters in Biogenic Drug Manufacturing

Sonication introduces mechanical energy into liquids through acoustic cavitation – the formation and collapse of microscopic bubbles. In pharmaceutical and biotech manufacturing, this translates into several decisive advantages:

1. Enhanced extraction efficiency
   Sonication disrupts plant cell walls, releasing intracellular bioactive compounds rapidly and reproducibly. Compared to conventional extraction, yields are higher, solvent use is lower, and processing times are dramatically reduced.
2. Controlled nanosynthesis
   In green nanoparticle synthesis, sonication promotes uniform nucleation and limits uncontrolled growth. This leads to narrow particle size distributions, a critical parameter for drug delivery, biodistribution, and safety.
3. Mild processing conditions
   Ultrasonic extraction and synthesis can be performed at low temperatures. That matters when working with heat-sensitive biomolecules such as enzymes, antioxidants, or sulfur-containing compounds like sulforaphane from broccoli.
4. Scalability and reproducibility
   Unlike batch-dependent chemical reactions, ultrasonic processes scale linearly. With the right equipment, lab-scale protocols can be transferred directly to pilot or industrial production.

In short, sonication is not just faster – it is more precise.

UV–visible spectral analysis confirming the formation of AuNPs synthesized using Brassica oleracea var. italica extract. The SPR peak at 560 nm indicates the successful reduction of Au3+ to Au⁰ and the formation of stable, phytochemical-capped AuNPs.